Section
Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
This review synthesizes motivations, facilitators, and barriers of donation-based interventions in HIV/STI research, revealing key factors that enhance access to services through prosocial behaviors in diverse global settings.
This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV r
Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.
A multicentre randomized trial evaluated adjunctive corticosteroids in HIV-negative severe Pneumocystis jirovecii pneumonia, showing a non-significant reduction in 28-day mortality and no safety concerns, and calls for further targeted rese
A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patient
This mixed-methods study assesses a novel Adolescent and Young Adult Healthcare Transition (AYA HCT) clinic that achieved high retention but suboptimal viral suppression among youth with HIV, highlighting key strengths and barriers.
An observational study evaluates an AI chatbot’s usability in promoting HIV testing among men who have sex with men in Malaysia, showcasing potential improvements for public health interventions.
A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
The DoxyPEP trial demonstrates that doxycycline post-exposure prophylaxis markedly lowers bacterial STI incidence in men who have sex with men and transgender women, with good tolerability and minimal resistance over 12 months.
TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.
Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.
Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.
A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.
